Immunartes

Cover Block

Company	Immunartes
Tagline	Biotech developing vaccines and antibody therapeutics against infectious diseases, with a focus on S. aureus.
Headquarters	Chicago, United States
Founded	2017
Stage	Pre-Seed
Business Model	Other
Industry	Deeptech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	Undisclosed
Total Disclosed	$10.58M (non-dilutive grants)

• Website: https://www.immunartes.com
• LinkedIn: https://www.linkedin.com/company/immunartes
• X / Twitter: https://twitter.com/Immunartes
• Crunchbase: https://www.crunchbase.com/organization/immunartes

Summary and Signal

Immunartes is a preclinical-stage biotech pursuing a preventive vaccine for Staphylococcus aureus, a pathogen responsible for significant hospital-acquired infections and a major driver of antimicrobial resistance [Immunartes, Dec 2022]. Founded in 2017 by University of Chicago-affiliated scientists, the company relies on grant capital from major public health entities [Devex]. Its scientific wedge is a proprietary antigen discovery and delivery platform designed to elicit protective immune responses against pathogens that have historically evaded vaccine development, with preclinical data showing protection against both MRSA and MSSA strains [Immunartes].

The founding team, led by CEO Vilasack Thammavongsa and CSO Dominique Missiakas, brings deep academic expertise in microbiology and immunology from the University of Chicago [Crunchbase]. The business model is oriented around achieving preclinical and early clinical milestones funded by contracts like the up-to-$10.4 million award from the National Institute of Allergy and Infectious Diseases (NIAID) and non-dilutive funding from the global AMR accelerator CARB-X [Immunartes, Dec 2022] [CARB-X]. Over the next 12-18 months, the key inflection points to watch are the progression of the lead vaccine candidate into formal IND-enabling studies and any shift in capitalization strategy.

Data Accuracy: YELLOW -- Core product and grant details are confirmed by company and funder announcements; team backgrounds and funding history are partially corroborated by secondary databases.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	Other
Industry / Vertical	Deeptech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	Undisclosed

Company Overview

Immunartes is a Chicago-based biotechnology company founded in 2017 by a group of University of Chicago-affiliated scientists and clinicians [Immunartes]. The company's formation was an academic spinout, rooted in research on microbiology, immunology, and infectious diseases [Immunartes]. Its legal entity is Immunartes LLC, and its public narrative frames its mission as developing vaccines and therapeutics against difficult infectious disease targets, with an initial focus on Staphylococcus aureus [Immunartes, Dec 2022].

Key corporate milestones have been tied to securing non-dilutive funding for preclinical development. In December 2017, the company received a grant [Crunchbase, Dec 2017]. In December 2022, Immunartes announced a contract award of up to $10.4 million from the National Institute of Allergy and Infectious Diseases (NIAID) for the advanced development of its S. aureus vaccine candidate [Immunartes, Dec 2022]. The company has also received non-dilutive funding from the global antimicrobial resistance accelerator CARB-X [CARB-X].

Data Accuracy: GREEN -- Company website and federal contract announcement corroborate founding and key funding milestones; grant data confirmed by Crunchbase.

The Product and the Stack

Immunartes is developing a vaccine candidate against Staphylococcus aureus infections. The company's primary technical claim is that its proprietary antigen discovery and delivery platform can elicit protective immune responses against pathogens that have historically been difficult vaccine targets [Immunartes]. Its lead program is designed to target both methicillin-resistant (MRSA) and methicillin-sensitive (MSSA) strains [Immunartes, Dec 2022].

According to the company, the vaccine candidate uses novel antigen combinations and delivery systems, which have shown protection in preclinical models [Immunartes, Dec 2022]. The platform is also described as enabling the development of antibody-based therapeutics [Immunartes] [CARB-X].

Data Accuracy: GREEN -- Product claims and technology description are confirmed by the company's own publications and a CARB-X funding announcement.

The Market They Are Entering

The pursuit of a vaccine for Staphylococcus aureus represents a high-value target in infectious disease, driven by the clinical and economic burden of antibiotic-resistant infections.

The U.S. Centers for Disease Control and Prevention (CDC) categorizes MRSA as a serious threat, estimating it causes over 323,000 infections and more than 10,000 deaths annually in the United States [CDC]. The global market for all bacterial vaccines was valued at approximately $27.5 billion in 2022 [Precedence Research, 2023].

Demand drivers are anchored in public health imperatives. The primary tailwind is the accelerating global antimicrobial resistance (AMR) crisis. Organizations like CARB-X explicitly fund projects like Immunartes's to address this gap [CARB-X]. A second driver is the economic pressure on hospitals to reduce costly hospital-acquired infections (HAIs).

Metric	Value
Global Bacterial Vaccine Market (2022)	$27.5B
Estimated Annual U.S. MRSA Infections	323,000

Data Accuracy: YELLOW -- Market sizing is inferred from analogous reports and public health data; specific TAM/SAM for an S. aureus vaccine is not publicly disclosed by the company or in cited sources.

The Competitive Field

Immunartes operates in a high-stakes, capital-intensive arena where its primary competition comes from established pharmaceutical giants and well-funded biotech challengers. The field for a Staphylococcus aureus vaccine is dominated by large-cap pharmaceutical companies. Pfizer has advanced a bivalent vaccine candidate (PF-06928316) into Phase 2 trials [PUBLIC]. GlaxoSmithKline also has a history of S. aureus vaccine research.

Immunartes's defensible edge today rests on its proprietary antigen discovery platform and its strong academic roots at the University of Chicago [Immunartes]. This scientific foundation has been credible enough to secure non-dilutive funding from major public health entities like the National Institute of Allergy and Infectious Diseases (NIAID) and CARB-X [Immunartes, Dec 2022][CARB-X].

Data Accuracy: YELLOW -- Competitive analysis is inferred from the company's stated focus and general market knowledge, as no direct competitors are named in captured sources.

Opportunity

The prize for Immunartes is a first-to-market prophylactic vaccine for a major hospital-acquired infection. The plausibility of this outcome is anchored in the company's alignment with major public health priorities, evidenced by its receipt of a $10.4 million contract from the NIAID [Immunartes, Dec 2022].

Scenario	What happens	Catalyst
Hospital Formulary Adoption	The vaccine is adopted by major hospital networks for pre-surgical administration to high-risk patients.	Successful completion of a Phase 3 clinical trial.
National Immunization Program Inclusion	The vaccine is incorporated into national immunization schedules for specific high-risk groups.	Positive recommendation from a national advisory committee.

Data Accuracy: YELLOW -- Opportunity size and comparables are inferred from public market data; company-specific growth catalysts are supported by cited grant announcements and public health framing.

Sources

1. [Immunartes, Dec 2022] Immunartes News | https://www.immunartes.com/uploads/2/6/5/0/26506652/immunartes_news_.pdf
2. [Devex] ImmunArtes | Devex | https://www.devex.com/organizations/immunartes-140566
3. [Immunartes] Our Technology | https://www.immunartes.com/our-technology.html
4. [Crunchbase] ImmunArtes - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/immunartes
5. [Crunchbase, Dec 2017] Grant - ImmunArtes - 2017-12-06 - Crunchbase Funding Round Profile | https://www.crunchbase.com/funding_round/immunartes-grant--03bcb4f7
6. [CARB-X] CARB-X funds Immunartes to develop Staphylococcus aureus preventative | https://carb-x.org/carb-x-news/carb-x-funds-immunartes-to-develop-staphylococcus-aureus-preventative/
7. [CDC] Antibiotic Resistance Threats in the United States, 2019 | https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
8. [Precedence Research, 2023] Bacterial Vaccines Market Size, Share, Growth Report 2032 | https://www.precedenceresearch.com/bacterial-vaccines-market
9. [Pfizer Annual Report, 2024] Pfizer Inc. 2023 Financial Report | https://s28.q4cdn.com/781576035/files/doc_financials/2023/ar/PFE-2023-Form-10K.pdf
10. [GSK, May 2022] GSK to acquire Affinivax | https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-affinivax/